Yong-Xia Bao1, Xiao-Dan Zhao2, Hong-Bin Deng3, Chang-Lian Lu4, Yang Guo5, Xing Lu3, Li-Li Deng6. 1. Department of Respiratory Medicine, The Second Affiliated Hospital of Harbin Medical University, 246 Xuefu Road, Nangang District, Harbin, 150086, Heilongjiang, People's Republic of China. 2. Department of Laboratory, The Second Affiliated Hospital of Harbin Medical University, 246 Xuefu Road, Nangang District, Harbin, 150086, Heilongjiang, People's Republic of China. 3. Dental Hospital, The First Affiliated Hospital of Harbin Medical University, 150001, 23 Youzheng Road, Nangang District, Harbin, Heilongjiang, People's Republic of China. 4. Department of Biopharmaceutical Sciences, College of Pharmacy, Harbin Medical University, 157 Baojian Rd, Harbin, 150081, Heilongjiang, People's Republic of China. 5. Department of Oncology, The Second Affiliated Hospital of Harbin Medical University, 246 Xuefu Road, Nangang District, Harbin, 150086, Heilongjiang, People's Republic of China. 6. Department of Oncology, The Second Affiliated Hospital of Harbin Medical University, 246 Xuefu Road, Nangang District, Harbin, 150086, Heilongjiang, People's Republic of China. dengdoctor@126.com.
Abstract
BACKGROUND: Non-small cell lung cancer (NSCLC) patients who do initially respond to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) may eventually develop resistance, which may at least partly be due to the acquisition of a secondary EGFR mutation (T790M). Additionally, it has been found that KRAS mutations may serve as poor prognostic biomarkers. Here, we aimed at establishing a suitable treatment regimen for the multi-target TKI sunitinib and the tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) in NSCLC-derived cells with or without EGFR and KRAS mutations. METHODS: Four NSCLC-derived cell lines with or without EGFR and KRAS mutations were exposed to different sunitinib and TRAIL treatment regimens. Alterations in cell viability, cell cycle distribution, apoptosis, phosphorylation of AKT and expression of the death receptors DR4 and DR5 were evaluated using CCK8, flow cytometry and Western blotting assays, respectively. RESULTS: A synergistic cytotoxic effect was observed in all four cell lines treated with sunitinib (1 nM) followed by TRAIL (100 ng/ml), as well as after simultaneous treatment with both agents. We found that sunitinib enhances TRAIL-induced G0/G1-phase cell cycle arrest and blocks TRAIL-triggered activation of AKT as the underlying mechanism. In contrast, we observed antagonistic effects when sunitinib was administered after TRAIL to the cell lines tested. A decreased DR4 and DR5 expression was found to be correlated with this antagonism. CONCLUSION: From our data we conclude that administration of sunitinib followed by TRAIL, as well as a simultaneous administration of both agents, serve as favorable treatment regimens for NSCLC-derived cells, irrespective of their EGFR and/or KRAS mutation status.
BACKGROUND:Non-small cell lung cancer (NSCLC) patients who do initially respond to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) may eventually develop resistance, which may at least partly be due to the acquisition of a secondary EGFR mutation (T790M). Additionally, it has been found that KRAS mutations may serve as poor prognostic biomarkers. Here, we aimed at establishing a suitable treatment regimen for the multi-target TKI sunitinib and the tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) in NSCLC-derived cells with or without EGFR and KRAS mutations. METHODS: Four NSCLC-derived cell lines with or without EGFR and KRAS mutations were exposed to different sunitinib and TRAIL treatment regimens. Alterations in cell viability, cell cycle distribution, apoptosis, phosphorylation of AKT and expression of the death receptors DR4 and DR5 were evaluated using CCK8, flow cytometry and Western blotting assays, respectively. RESULTS: A synergistic cytotoxic effect was observed in all four cell lines treated with sunitinib (1 nM) followed by TRAIL (100 ng/ml), as well as after simultaneous treatment with both agents. We found that sunitinib enhances TRAIL-induced G0/G1-phase cell cycle arrest and blocks TRAIL-triggered activation of AKT as the underlying mechanism. In contrast, we observed antagonistic effects when sunitinib was administered after TRAIL to the cell lines tested. A decreased DR4 and DR5 expression was found to be correlated with this antagonism. CONCLUSION: From our data we conclude that administration of sunitinib followed by TRAIL, as well as a simultaneous administration of both agents, serve as favorable treatment regimens for NSCLC-derived cells, irrespective of their EGFR and/or KRAS mutation status.
Authors: Giovenzio Genestreti; Francesco Grossi; Carlo Genova; Marco A Burgio; Alberto Bongiovanni; Giampaolo Gavelli; Marco Bartolotti; Monica Di Battista; Giovanna Cavallo; Alba A Brandes Journal: Future Oncol Date: 2014-10 Impact factor: 3.404
Authors: Bernard Escudier; Camillo Porta; Petri Bono; Thomas Powles; Tim Eisen; Cora N Sternberg; Jürgen E Gschwend; Ugo De Giorgi; Omi Parikh; Robert Hawkins; Emmanuel Sevin; Sylvie Négrier; Sadya Khan; Jose Diaz; Suman Redhu; Faisal Mehmud; David Cella Journal: J Clin Oncol Date: 2014-03-31 Impact factor: 44.544
Authors: Erich Piovan; Jiyang Yu; Valeria Tosello; Daniel Herranz; Alberto Ambesi-Impiombato; Ana Carolina Da Silva; Marta Sanchez-Martin; Arianne Perez-Garcia; Isaura Rigo; Mireia Castillo; Stefano Indraccolo; Justin R Cross; Elisa de Stanchina; Elisabeth Paietta; Janis Racevskis; Jacob M Rowe; Martin S Tallman; Giuseppe Basso; Jules P Meijerink; Carlos Cordon-Cardo; Andrea Califano; Adolfo A Ferrando Journal: Cancer Cell Date: 2013-11-27 Impact factor: 31.743
Authors: John D Schneible; Kaihang Shi; Ashlyn T Young; Srivatsan Ramesh; Nanfei He; Clay E Dowdey; Jean Marie Dubnansky; Radina L Lilova; Wei Gao; Erik Santiso; Michael Daniele; Stefano Menegatti Journal: J Mater Chem B Date: 2020-05-06 Impact factor: 6.331